Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors
Status:
Active, not recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of Gemzar®
(gemcitabine) and Adriamycin® (doxorubicin) that can be given together with Velcade®
(bortezomib) in patients with urothelial cancer or other solid tumors.